Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros

Base de dados
Ano de publicação
Tipo de documento
Assunto da revista
País de afiliação
Intervalo de ano de publicação
1.
J Appl Toxicol ; 44(2): 216-234, 2024 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-37646119

RESUMO

Serotonergic psychedelics, such as lysergic acid diethylamide (LSD), psilocybin, dimethyltryptamine (DMT), and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), are currently being investigated for the treatment of psychiatric disorders such as depression and anxiety. Clinical trials with psilocybin and LSD have shown improvement in emotional and psychological scores. Although these drugs are reported to be safe in a controlled environment (such as clinical trials), exposure to low doses of these drugs can result in psychedelic effects, and therefore, occupational safety is an important consideration to prevent adverse effects in the workplace from low daily exposure. This article will discuss the factors involved in the derivation of occupational exposure limits (OELs) and risk assessment of these psychedelic drugs. To support the OEL derivations of psychedelic drugs, information regarding their mechanism of action, adverse effect profiles, pharmacokinetics, clinical effects, and nonclinical toxicity were considered. Additionally, psilocybin and LSD, which are the most extensively researched psychedelic substances, are employed as illustrative examples in case studies. The OELs derived for psilocybin and for LSD are 0.05 and 0.002 µg/m3 , respectively, which indicates that these are highly hazardous compounds, and it is important to take into account suitable safety measures and risk-management strategies in order to minimize workplace exposure.


Assuntos
Alucinógenos , Humanos , Alucinógenos/toxicidade , Alucinógenos/uso terapêutico , Psilocibina/toxicidade , Psilocibina/uso terapêutico , Dietilamida do Ácido Lisérgico/toxicidade , Dietilamida do Ácido Lisérgico/uso terapêutico , N,N-Dimetiltriptamina , Medição de Risco
2.
Toxicol Mech Methods ; 21(2): 93-6, 2011 Feb.
Artigo em Inglês | MEDLINE | ID: mdl-20507226

RESUMO

Occupational exposure to active pharmaceutical ingredients in a manufacturing or laboratory environmental can cause unintended health effects in workers handling these compounds. Occupational health professionals in the pharmaceutical industry have responded to this hazard recognition by employing strategies for the risk evaluation and management of potent APIs, otherwise known by the term 'potent compounds'. The purpose of this paper is to provide an overview of the necessary strategy components for preventing occupational exposure to potent compounds.


Assuntos
Indústria Farmacêutica , Efeitos Colaterais e Reações Adversas Relacionados a Medicamentos , Doenças Profissionais/prevenção & controle , Exposição Ocupacional/prevenção & controle , Saúde Ocupacional , Animais , Monitoramento Ambiental , Humanos , Nível de Efeito Adverso não Observado , Doenças Profissionais/induzido quimicamente , Exposição Ocupacional/efeitos adversos , Medição de Risco , Especificidade da Espécie
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA